

Chapter name	St. Petersburg
President	Alexey S. Kolbin
President-Elect	Sergey K. Zyryanov
Past President	
Secretary	Alexey A. Kurylev
Treasurer	Alexey A. Kurylev
Director	Dmitry Yu. Belousov
Director	
Director	
Other, non-Board positions (please list if applicable)	
When are elections held for the Chapter Board? (Please describe how the election process is organized and indicate the term length for the Board members.)	Elections are held every 2 years
Full ISPOR members as of December 2018 (those paying dues to ISPOR Headquarters)	12
Regional Chapter Members - 2017	12
Regional Chapter Members - 2018	12
In terms of membership composition, approximately what percentage of your Chapter members primarily work in:	
Academia%	100
Government/HTA Agency%	
Industry - Pharmaceutical/Medical Device/Diagnostics/ Biotech%	
Consulting%	
Clinicians%	
Students%	
Other%	
Did the Chapter collect membership dues or fees from individuals for local Chapter membership?	No
Did the Chapter hold regular meetings (e.g., Annual Chapter meetings) with members?	6 times a year
What channels of communication did the Chapter use to stay in contact with members: email blast, newsletter, social media, website? Please provide examples where applicable.	email blast, website

Does the Chapter have a strategy for increasing membership?	We use student scientific community and training courses.
What steps did the Chapter take to retain and recruit new members in the past year?	We use student scientific community and training courses.
What benefits did the Chapter offer to the members?	Access to training resources and participation in pharmaco-economic researches
Did the Chapter have any groups formed within the Chapter? If yes, please indicate the name of these groups, its focus/purpose and if it is a new group (formed in the past year) or an established group:	No
Did the Chapter discontinue any groups in the past year?	No
How did your Chapter engage members in its activities in the past year?	
Presentations in Chapter meetings (when was it held, topic)	
Seminars (please describe the topic and time it was held)	1. On the base of Pavlov First Saint Petersburg State Medical University an educational course for doctors was organized and conducted, as a part of continuing medical education (the course information is posted on the Continuing Medical and Pharmaceutical Education Portal (http://edu.rosminzdrav.ru/): "Current Issues of Health Technology Assessment", March 2018 2. On the base of Pavlov First Saint Petersburg State Medical University an educational course for doctors was organized and taught, as a part of continuing medical education (the course information is posted on the Continuing Medical and Pharmaceutical Education Portal (http://edu.rosminzdrav.ru/): "Current Issues of Health Technology Assessment", October 2018 3. At the North-Western State Medical University named after I.I. Mechnikov, the issues of health technology assessment were introduced in the Master's programs majoring in Public Health and included in the medical residency program majoring in Healthcare Organization and Public Health. 4. At the St. Petersburg State Chemical Pharmaceutical Academy, the Pharmaco-economic Analysis course is included in the basic part of the medical residency education program majoring in Management and Economics of Pharmacy, as well as in the educational program for students of the pharmaceutical faculty majoring in Pharmacy.
Webinars (topic and time)	
Articles in Chapter newsletter	
Articles/contributions to Chapter website (if available)	
Chapter meetings/gatherings at ISPOR events	
Other (please describe the activity and when it was held)	
Did your Chapter offer education and training opportunities to its members?	Yes
In-person Workshops on HTA (time and topic)	
In-person Workshop on HEOR (time and topic)	

In-person Workshops on other topics (please describe)	
In-person Lectures on HTA (time and topic)	1. On the base of Pavlov First Saint Petersburg State Medical University an educational course for doctors was organized and conducted, as a part of continuing medical education (the course information is posted on the Continuing Medical and Pharmaceutical Education Portal (http://edu.rosminzdrav.ru/): "Current Issues of Health Technology Assessment", March 2018 2. On the base of Pavlov First Saint Petersburg State Medical University an educational course for doctors was organized and taught, as a part of continuing medical education (the course information is posted on the Continuing Medical and Pharmaceutical Education Portal (http://edu.rosminzdrav.ru/): "Current Issues of Health Technology Assessment", October 2018 3. At the North-Western State Medical University named after I.I. Mechnikov, the issues of health technology assessment were introduced in the Master's programs majoring in Public Health and included in the medical residency program majoring in Healthcare Organization and Public Health. 4. At the St. Petersburg State Chemical Pharmaceutical Academy, the Pharmacoeconomic Analysis course is included in the basic part of the medical residency education program majoring in Management and Economics of Pharmacy, as well as in the educational program for students of the pharmaceutical faculty majoring in Pharmacy.
In-person Lectures on HEOR (time and topic)	
In-person Lectures on other topics (please describe)	1. Within the framework of the VI All-Russian conference with international participation "Current issues of preclinical and clinical studies of drugs, biomedical cell products and clinical trials of medical devices", the "Health Technology Assessment" section was organized and held (April 20, 2018). 2. Within the framework of the IV St. Petersburg International Oncology Forum, the "Health Technology Assessment" section was held (July 8, 2018). 3. Within the framework of the St. Petersburg Septic Forum, the "Health Technology Assessment" section was held (September 12, 2018).
Webinars on HTA (time and topic)	
Webinars on HEOR (time and topic)	
Webinar on other topics (please describe)	
Other training/education opportunities (please describe)	
Did your Chapter members participate in research activities?	Yes
If yes, which of the following did your members participate in:	
ISPOR Task Forces (name of the Task Force)	1. Participation in the ISPOR – CEE HTA Training and Education Project
ISPOR SIGs (name of the SIG)	
National/Regional research projects (please indicate which ones)	1 Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes, and capecitabine 2 Clinical trial results and real-world medical evidence gap: literature overview. 3 Simulation of bacterial resistance for different antibiotic consumption strategies based on the Escherichia coli resistance to cephalosporins 4 Network meta-analysis for Parnaparine effectiveness in venous thromboembolic prevention in surgery 5 CYP2D6 genotyping in the daily routine of a psychiatric hospital - pharmacoeconomic evaluation 6 Modeling microbial drug-resistance: from mathematics to Pharmacoeconomics 7 Complicated intra-abdominal infection at multidisciplinary hospital: economics of real practice of antimicrobial

	<p>treatment 8 Pharmacoeconomic evaluation of mirabegron: results of the healthcare budget impact analysis 9 Pharmacoeconomic analysis of dexamethasone intravitreal implant for the treatment of diabetic macular edema in Russia 10 Socioeconomic burden of atrial fibrillations in Russia: seven-year trends (2010-2017) 11 Optimization Approach for Estimating the Required Amount of Pharmaceuticals in the Russian Federation 12 Analysis of consumption of antibacterial drugs for systemic use in hospitals of Saint Petersburg in 2014–2015 13 Clinical and economic evaluation of treatment of lysosomal acid lipase deficiency 14 What is the role of antineoplastic drug safety in reimbursement decision making? 15 Cost-benefit analysis of regimens of antibacterial therapy for acute uncomplicated pyelonephritis 16 Forecasting economic effect of Alirocumab in patients with hypercholesteremia and high cardiovascular risk 17 Pharmacoeconomic study of drugs used in the treatment of moderate and severe psoriasis in patients with ineffective basic systemic therapy 18 A problem of inhaled drug substitutions: analysis of data from the Russian database on adverse events 19 Pharmacoeconomic assessment of dual bronchodilation therapy in patients with COPD 20 Perspectives for use of the radionuclide drugs in the treatment of malignant tumors in Russia 21 Pharmacoeconomic analysis of flexible-dose administration regimen of Xeomine® in patients with focal dystonia 22 GCP inspection by Roszdravnadzor 23 Pharmacoeconomic analysis of chronic heart failure drug therapy in patients with comorbid conditions 24 Resolution of the Expert Council “Empirical antibacterial therapy of respiratory infections and the risk factors of resistant flora” 25 Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropium-olodaterol in patients with chronic obstructive pulmonary disease 26 Pharmacoeconomic Analysis of Afatinib and Gefitinib for the Treatment of Lung Cancer 27 Experience of studying the medical and social characteristics of patients receiving chemotherapy in a specialized hospital. 28 Clinical and pharmacoeconomic aspects of neoadjuvant therapy of breast cancer 29 Economic losses due to low coverage of lipid-lowering therapy in patients with cardiovascular diseases in the Russian Federation 30 Economic burden of hypercholesterolemia in the Russian Federation 31 Vaccine prevention of pneumococcal infection in children 32 Economic feasibility of new chemotherapy regimens for treatment of tuberculosis patients with extensive drug resistance 33 Vaccination against pneumococcal infections in Russian Federation: social and pharmacoeconomic aspects 34 Use of highly concentrated polyunsaturated fatty acids for prevention of complications after myocardial infarction. Cost-Utility analysis 35 Pharmacoeconomic analysis of Cellex® in the treatment of ischemic stroke 36 Clinical and economic analysis of PD-1 inhibitors and combinations of BRAF and MEK inhibitors for the treatment of metastatic melanoma with a BRAF V600 gene mutation 37 Pharmacoeconomic analysis of different methods for the treatment of steroid-refractory graft-versus-host disease: single-center study 38 Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia 39 Clinical and economic analysis of the use of antipsychotic drugs in hospital for the treatment of schizophrenia 40 Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia 41 Pharmacoeconomic expediency of using the coformulated Vezomni in comparison with a combination of Tamsulosin and Solifenacin in the form of single entity tablets</p>
Other research activities (please describe)	
Did your Chapter contribute to any health policy-related activities on national/regional level?	<p>1. Participation in the Working Group on Monitoring Law Enforcement Practices of the Rules for the Compiling Restrictive Drug Lists of the Russian Federation Ministry of Health 2. Development of separate sections and editing of the document “On Approval of the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the Period up to 2030”. 3. Working as experts for two Expert Organizations under the Ministry of Health of the Russian Federation in the formalized system of the Rules for the lists of drug formation: St. Petersburg State Medical University named after acad. I.P. Pavlov; North-West State Medical University named after I.I. Mechnikov</p>
Did your Chapter organize/contribute to the organization of the regional/international events in the past year? If yes, please indicate event title,	Yes

<p>date, location, attendance number (if available), and type of contribution.</p>	
<p>List articles published in ISPOR's publications in 2018 - Value in Health, Value in Health Regional Issues, Value and Outcomes Spotlight, and ISPOR Regional newsletters by Chapter members. Please indicate article title, author's name, issue number.</p>	<p>Optimization Approach for Estimating the Required Amount of Pharmaceuticals in the Russian Federation Value in Health Regional Issues. 2018;16:39-45. DOI: 10.1016/j.vhri.2018.04.002 Prasolov, A.V., Kolbin, A.S., Balykina, Y.E.</p>
<p>List Chapter contributions to ISPOR events by Chapter members in 2018. For example: presented posters, Forums, Chapter meetings.</p>	<p>1 ISPOR 21th Annual European Congress Pharmacoeconomic Study of the Effectiveness and Safety of Antipsychotics November 10-14, 2018, Barcelona, Spain 2 ISPOR 21th Annual European Congress Influence of the Time Horizon Length on the Results of Pharmacoeconomic Research November 10-14, 2018, Barcelona, Spain 3 ISPOR 21th Annual European Congress The Use of Obinutuzumab in Treatment of Refractory and Relapsing Follicular Lymphoma November 10-14, 2018, Barcelona, Spain 4 ISPOR 21th Annual European Congress Health-Economic Evaluation of Pharmacogenetic Tests in Psychiatric In-Patient Care November 10-14, 2018, Barcelona, Spain 5 ISPOR 2018 Estimated Budget Impact of Cholesterol Decreasing in the Russian Population May 19–23, Baltimore, USA 6 ISPOR 2018 Social and Economic Impact of Diabetes Mellitus Type 2 and it's Cardiovascular Complications on the Workforce in the Russian Federation May 19–23, Baltimore, USA 7 ISPOR 21th Annual European Congress Pharmacoeconomic Evaluation of Pharmacological Treatment Options for Patients with Moderately-Severe and Severe Psoriasis and Resistance to the Base Therapy November 10-14, 2018, Barcelona, Spain 8 ISPOR 21th Annual European Congress Pharmacoeconomic Analysis of Drug Therapy of Chronic Heart Failure in Patients with Comorbid Conditions November 10-14, 2018, Barcelona, Spain 9 ISPOR 21th Annual European Congress Economic Assessment of Effectiveness and Safety of Common Practice Perioperative Antibiotic Prophylaxis in a Multidisciplinary Hospital November 10-14, 2018, Barcelona, Spain 10 ISPOR 21th Annual European Congress The Structure of Consumption of Antimicrobial Drug for Systemic Use in Multidisciplinary Hospitals in St. Petersburg in 2014-2015 November 10-14, 2018, Barcelona, Spain 11 ISPOR 21th Annual European Congress Pharmacoeconomic Modes of Antibiotic Therapy of Uncomplicated Community-Acquired Acute Pyelonephritis in a Multidisciplinary Hospitals November 10-14, 2018, Barcelona, Spain 12 ISPOR Asia Pacific 2018. Value-based decision making in developing countries: multi-criteria decision analysis (MCDA) for off-patent pharmaceuticals Multicriteria Decision Analysis in Russia September 8-11, 2018, Tokyo, Japan 13 ISPOR 21th Annual European Congress Pharmacoeconomic Analysis of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis November 10-14, 2018, Barcelona, Spain 14 ISPOR 21th Annual European Congress Pharmacoeconomics of Different Treatments for Steroid-Refractory Graft Versus Host Disease: Analysis of Treatment Results in a Single-Center Study November 10-14, 2018, Barcelona, Spain</p>
<p>Have your chapter participated in the "ISPOR Chapter Leadership Workshop"?</p>	<p>No</p>
<p>Other than the page for the Chapter on the ISPOR website, does the Chapter maintain a website as of December 2018?</p>	<p>http://www.labclinpharm.ru ↗ http://www.healtheconomics.ru ↗ http://hta.labclinpharm.ru ↗ YouTube channel: https://www.youtube.com/playlist?list=PLrajN8RdEiYoRDKBcWVdhyawjsTJ8rUIQ</p>
<p>Describe Chapter regional patient engagement activities in the past year (if applicable). For example: collaboration with patient engagement organizations (rare disease, EUPATI), events or conferences with patient engagement focus.</p>	

<p>Describe Chapter HTA-focused activities in the past year if applicable. For example: collaboration with regional and national HTA bodies, events or conferences with HTA focus, development of PE guidelines.</p>	<p>IX. Educational Programs and Seminars 1. On the base of Pavlov First Saint Petersburg State Medical University an educational course for doctors was organized and conducted, as a part of continuing medical education (the course information is posted on the Continuing Medical and Pharmaceutical Education Portal (http://edu.rosminzdrav.ru/): “Current Issues of Health Technology Assessment”, March 2018 2. On the base of Pavlov First Saint Petersburg State Medical University an educational course for doctors was organized and taught, as a part of continuing medical education (the course information is posted on the Continuing Medical and Pharmaceutical Education Portal (http://edu.rosminzdrav.ru/): “Current Issues of Health Technology Assessment”, October 2018 3. At the North-Western State Medical University named after I.I. Mechnikov, the issues of health technology assessment were introduced in the Master’s programs majoring in Public Health and included in the medical residency program majoring in Healthcare Organization and Public Health. 4. At the St. Petersburg State Chemical Pharmaceutical Academy, the Pharmacoeconomic Analysis course is included in the basic part of the medical residency education program majoring in Management and Economics of Pharmacy, as well as in the educational program for students of the pharmaceutical faculty majoring in Pharmacy. X. Organizational Work 1. Within the framework of the VI All-Russian conference with international participation “Current issues of preclinical and clinical studies of drugs, biomedical cell products and clinical trials of medical devices”, the “Health Technology Assessment” section was organized and held (April 20, 2018). 2. Within the framework of the IV St. Petersburg International Oncology Forum, the “Health Technology Assessment” section was held (July 8, 2018). 3. Within the framework of the St. Petersburg Septic Forum, the “Health Technology Assessment” section was held (September 12, 2018).</p>
<p>Does the Chapter have any research or health policy-focused groups formed within the Chapter? For example: local SIG groups, Medical Devices, Clinicians.</p>	<p>1. Participation in the Working Group on Monitoring Law Enforcement Practices of the Rules for the Compiling Restrictive Drug Lists of the Russian Federation Ministry of Health 2. Development of separate sections and editing of the document “On Approval of the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the Period up to 2030”. 3. Working as experts for two Expert Organizations under the Ministry of Health of the Russian Federation in the formalized system of the Rules for the lists of drug formation: St. Petersburg State Medical University named after acad. I.P. Pavlov; North-West State Medical University named after I.I. Mechnikov</p>
<p>Did the Chapter engage with students in your region in the past year?</p>	<p>No</p>
<p>Did the Chapter engage with new professionals in your region in the past year?</p>	<p>No</p>
<p>Does your Chapter have links to ISPOR Student Chapters in your country/region as of December 2018?</p>	<p>No</p>
<p>Please indicate Chapter affiliations with any institutions, universities, government, or associations (other than ISPOR) in the past year.</p>	<p>1. Participation in the work of the All-Russian Association of Clinical Pharmacologists 2. Participation in the work of the Educational Methodical Committee on Clinical Pharmacology under the Ministry of Health of the Russian Federation</p>
<p>Did the Chapter have any agreements of sponsorship arrangements with any for-profit companies, governments, health authorities, or associations in the past year? Chapters are required to obtain written approval from ISPOR prior to developing contractual ongoing relationship with government entities, or other organizations.</p>	<p>No</p>

Did the Chapter as a group (not as individual members) submit any formal comments or responses to any review processes organized by a regional/national government or health authority? Chapters are required to obtain written approval from ISPOR prior to making recommendations concerning HEOR practices or policies to official government entities. ISPOR will respond within 30 days, or sooner if it's a time sensitive issue.	No
Is the Chapter officially registered with regional authorities in your country, i.e., is a Chapter a stand-alone legal entity as of December 2018?	Yes
Did the Chapter employ paid administrative or management staff (Association Management Company, contracted staff) in the past year?	No
Did the Chapter have a bank account in the past year?	No
What is the Chapter's official email address?	alex.kolbin@mail.ru
To advance HEOR in lower- and middle-income countries (LMICs), as defined by the World Bank, ISPOR offers benefits to members and Chapters in these countries. If your Chapter is located in an LMIC, do you value and use the current benefits? Are there additional benefits that you would like ISPOR to provide at the Chapter or individual member level? (click on links for further information)	No
What are the 3 major challenges the Chapter is facing at the end of 2018? How do you think ISPOR can help you in addressing these challenges? Please provide specific examples.	
1	Publication activity in international journals on the issues of Pharmacoeconomics and medical technology assessment
2	Publication Activity Value in Health
3	
Please attach the CV for the Chapter President.	X
Please complete and attach the Chapter's 2019 Annual Work Plan.	X
Who prepared this report? Please provide name and email address. ISPOR will reach out to this contact if there are questions regarding the report.	
Name	Professor Alexey S. Kolbin, MD, PhD, Doctor of Science, Head of the Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University; Yulia E. Balykina, PhD, associate professor, St Petersburg State University, faculty of Applied Mathematics and Control Processes.

Email	alex.kolbin@mail.ru
How can the ISPOR organization as a whole (Staff, Board, Consortia, Networks, etc.) better support your Chapter?	
Please acknowledge you have received the "ISPOR Chapter Logo: Usage Guidelines" If you have questions please contact your Global Networks liaison.	Yes, I have received the "ISPOR Chapter Logo: Usage Guidelines."